Form 4: PharmaCyte Biotech Director Acquires Stock Options

PharmaCyte Biotech Director Robert Weinstein acquired 119,170 stock options with an exercise price of $0.67, vesting on the next annual meeting date.

Summary

• Robert Weinstein, a Director at PharmaCyte Biotech, Inc., acquired 119,170 stock options.
• The options have an exercise price of $0.67 per share.
• These options are set to vest in full on the date of the Issuer's next annual meeting of stockholders, contingent upon Mr. Weinstein's continued service.
• The transaction date was March 31, 2026, with the report filed on April 2, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard insider stock option grant rather than a significant new development or financial result.

Positives

• Director Robert Weinstein's acquisition of stock options indicates a commitment to the company's future performance.
• The exercise price of $0.67 suggests a belief that the stock price will exceed this level, offering potential upside for the director.
• Vesting contingent on continued service aligns management's interests with long-term company success.

Risks

• The vesting of options is contingent on continued service, meaning any departure before the next annual meeting would result in forfeiture.
• The value of the options is directly tied to the future performance of PharmaCyte Biotech's stock price, which carries inherent market risk.

Future Outlook

The acquisition of stock options by a director suggests a positive outlook on the company's future stock performance, as the options will only be valuable if the stock price rises above the exercise price of $0.67.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biotechnology sector, often used as a long-term incentive to align executive interests with shareholder value and encourage sustained performance.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively, indicating confidence in future stock appreciation. However, it does not immediately impact share price or ownership structure.
• Employees: The vesting condition tied to continued service reinforces the importance of employee retention and performance for option holders.
• Management: Aligns the director's financial interests with the company's long-term success and stock performance.

Next Steps

• Robert Weinstein will continue his service as Director, subject to the terms of his employment.
• The stock options will vest on the date of the Issuer's next annual meeting of stockholders.

Key Dates

Keywords

PharmaCyte Biotech, PMCB, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Insider Trading